Evidence map›Paper›PMID 37354243›Full record

SynthesisNeurosurgical review2023

The incidence of radiation-induced moyamoya among pediatric brain tumor patients who received photon radiation versus those who received proton beam therapy: a systematic review.

Amr Elkatatny, Mohammed Ismail, Khaled Maemoun Moenes Ibrahim, Mohammed H Aly, Mohammed A Fouda

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Neurosurgical review, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Cerebrovascular and Peripheral Vascular Complications in Cancer Patients.Current neurology and neuroscience reports · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Amr ElkatatnyDepartment of Neurological Surgery, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt.
Mohammed IsmailDepartment of Neurological Surgery, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt.
Khaled Maemoun Moenes IbrahimDepartment of Neurological Surgery, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt.
Mohammed H AlyDepartment of Neurological Surgery, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt.
Mohammed A FoudaDepartment of Neurological Surgery, New York-Presbyterian Hospital, Weill Cornell Medicine, 525 E 68th Street, Box 99, New York, NY, 10065, USA. Maf4023@med.cornell.edu.ORCID http://orcid.org/0000-0001-8884-7289
Cairo University · EGNewYork–Presbyterian Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cranial irradiation is associated with several adverse events such as endocrinopathy, growth retardation, neurocognitive impairment, secondary malignancies, cerebral vasculopathy, and potential stroke. The better side effects profile of proton beam therapy compared with that of photon radiation therapy is due to its physical properties, mainly the sharp dose fall-off after energy deposition in the Bragg peak. Despite the better toxicity profile of proton beam therapy, the risk of  moyamoya syndrome still exists. We conducted a systematic review of the existing literature on moyamoya syndrome after receiving cranial radiation therapy for pediatric brain tumors to investigate the incidence of moyamoya syndrome after receiving photon versus proton radiation therapy. In this review, we report that the incidence of moyamoya syndrome after receiving proton beam therapy is almost double that of photon-induced moyamoya syndrome. Patients who received proton beam therapy for the management of pediatric brain tumors are more likely to develop moyamoya syndrome at the age of less than 5 years. Meanwhile, most patients with proton-induced moyamoya are more likely to be diagnosed within the first 2 years after the completion of their proton beam therapy.

Indexed as

Brain NeoplasmsMoyamoya DiseaseProton TherapyChildChild, PreschoolHumansIncidenceProtonsProtonsBrain tumorsCranial irradiationMoyamoya syndromePediatricPhotonProton beam therapy

Identifiers

PMID37354243
OpenAlexW4381856825

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.